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Abstract
The most frequently described drugs in the treatment of mood disorders are selective serotonin reuptake and monoamine oxidase (MAO)
inhibitors, enhancing serotonin levels in the brain. However, side-effects have been reported for these drugs. Because serotonin levels in
the brain are dependent on the availability of the food-derived precursor tryptophan, foods such as chicken, soyabeans, cereals, tuna, nuts
and bananas may serve as an alternative to improve mood and cognition. Here we discuss the effects of high- or low-tryptophan-
containing food, as well as plant extracts with a modest monoamine reuptake and MAO-A inhibition functional profile, on mood and
cognition in healthy and vulnerable human subjects and rodents. Together the studies suggest that there is an inverted U-shaped curve
for plasma tryptophan levels, with low and too high tryptophan levels impairing cognition, and moderate to high tryptophan levels
improving cognition. This relationship is found for both healthy and vulnerable subjects. Whereas this relationship may also exist for
mood, the inverted U-shaped curve for plasma tryptophan levels and mood may be based on different tryptophan concentrations in
healthy v. vulnerable individuals. Animal studies are emerging and allow further understanding of effects and the mode of action of
food-derived serotonergic components on mood, cognition and mechanisms. Ultimately, insight into the concentrations of tryptophan
and other serotonergic components in food having beneficial effects on mood and cognition in healthy, but particularly vulnerable,
subjects may support well-being in our highly demanding society.
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Introduction
Food is a primary requirement to live. Yet, even when food
is abundantly available, food could also be used as a
powerful tool to increase mental well-being. Stress-related
mental disorders such as mood or anxiety disorders are the
most prevalent (10 to 25 % women and 5 to 12 % men are
being diagnosed each year(1)), and burdensome, psychia-
tric disorders. They are characterised by low mood states
and cognitive impairments such as reduced learning and
memory(1). Thus, the exploitation of resilience or mood/
cognition-enhancing food is of extreme value. Yet,
whereas pharmacological manipulations have been abun-
dantly applied, surprisingly little is known about the effects
of food on mood and cognition.
The monoamine systems are strongly tied to stress
resilience and the (patho)physiology of mood and mood
disorders. As such, tricyclic antidepressants (inhibiting sero-
tonin and noradrenaline reuptake) and selective serotonin
reuptake inhibitors (SSRI) are frequently prescribed drugs
in the treatment of these disorders. To a limited extend
these agents also inhibit dopamine reuptake. Whereas anti-
depressant drugs are considered as healthy drugs, their
uncontrolled intake is not without risks. For instance, at
a young age these drugs may affect brain development
and increase suicide(2). Furthermore, triple monoamine
reuptake inhibition corresponds to the function of cocaine,
which is a powerful psychostimulant with abuse potential.
In addition to monoamine reuptake inhibitors, also drugs
that inhibit the breakdown of monoamines are used to
improve mood, particularly monoamine oxidase A (MAO-A)
inhibitors. However, these agents are also associated with
substantial side effects. A major risk is the serotonin
syndrome; too high levels of serotonin are toxic. Hence,
whereas monoamine reuptake inhibitors and MAO-A
inhibitors improve mood, particularly in individuals with a
low mood state, their use is not without risks.
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To improve mood by other means, food with high
tryptophan (Trp) availability and modest monoamine
reuptake and MAO-A inhibition functional profile may be
effective. The serotonin precursor Trp is an essential
amino acid that in mammals can only be derived from
food(3). Therefore, Trp levels in food appear to be an
essential link in the relationship between food intake and
our mood state. Accordingly, high-Trp-containing foods
(for example, chicken, soyabeans, cereals, tuna, nuts and
bananas) are presented on the Internet as food to improve
mood. Furthermore, sometimes unknowingly, the Trp
content of food has been increased. For instance, Neolithic
Mesopotamia-cultivated chickpeas contained more Trp
than wild varieties(4). Another example is the treatment
of maize with alkali by various cultures in America,
which enhances the bioavailability of Trp(5,6). More
recently, research into a-lactalbumin has revealed that
this whey-derived protein has the highest Trp content of
all proteins found in food and therefore is added to
infant milk formulas(7). Finally, an even more promising
source of Trp is egg protein hydrolysate(8). Pharmacologi-
cal studies have confirmed that products that increase
Trp levels increase serotonin levels in the brain, and appar-
ently modulate processing in the neurocircuits regulating
mood to enhance mood(9,10). Trp depletion, on the other
hand, is well known to affect mood negatively(11).
Hence, controlling the amount of Trp in food has substan-
tial effects on mood regulation and well-being, although
data as discussed in the present review indicate that the
relationship between Trp levels and mood is less
straightforward than we tend to think. Foods having
triple monoamine reuptake and MAO-A inhibitor function
have been less extensively investigated, even though they
may offer another natural source to boost mood. Indeed,
these foods have significant anti-depressive and anxiolytic
effects in rats which are comparable with the effects of
antidepressant reference drugs(12).
The aim of the present review is to provide an update
about foods influencing the serotonergic system that have
potential to increase stress resilience and thereby our
well-being. Rather than applying pharmacological drugs
when pathology has developed, prevention by healthy
foods may decrease the burden associated with mood dis-
orders. An important consideration is the heterogeneity of
mood disorders, caused by genetic or other biological
factors. Along with the fact that there are large individual
differences in vulnerability to mood disorders, there are
large individual differences in responsivity to antidepress-
ant agents(13), as well as in responsivity to serotonergic
food components. These individual differences play a lead-
ing role in our discussion of the effects of serotonergic
foods on mood. In sum, the present review discusses the
serotonergic system, and the influence of serotonergic
food components on mood and cognition in healthy,
genetically vulnerable and clinically depressed and recov-
ered populations, as well as (genetic) rodent models.
The serotonergic system
Serotonin, or 5-hydroxytryptamine (5-HT), is an ancient
monoamine, as even some unicellular organisms are able
to synthesise it. Furthermore, it is found in basically all
animal species and various plants such as stinging nettles
and walnuts. Apart from its roles in the cardiovascular and
digestive systems, 5-HT is an important neurotransmitter
with a wide variety of actions in different brain regions.
Because 5-HT as a hydrophilic molecule is unable to cross
the blood–brain barrier, it is synthesised in the brain, specifi-
cally the serotonergic neurons in the raphe nuclei itself,
by the enzyme tryptophan hydroxylase 2 (TpH2). TpH2 is
also expressed in myenteric neurons in the gut(14). TpH2
is distinct from tryptophan hydroxylase 1 (Tph1), the
enzyme that is responsible for the 5-HT system in the periph-
eral system, mainly the gut. The synthesis of 5-HT in the
brain takes place in the axon terminals of serotonergic neur-
ons where TpH2 exerts the first rate-limiting step. TpH2
hydroxylates L-tryptophan and forms 5-hydroxytryptophan.
This molecule is subsequently decarboxylated by aromatic
L-amino acid decarboxylase to form 5-HT. The 5-HT mol-
ecules are stored in vesicles in the serotonergic neurons.
Upon an action potential, 5-HT is released from axon term-
inals of serotonergic neurons into the synaptic cleft where it
binds to its receptors on the postsynaptic neuron. Its activity
is terminated by the serotonin transporter (5-HTT) in the
membrane of the presynaptic neuron that transports 5-HT
back into the cell. This allows recycling of 5-HT, although
stored/released 5-HT is also degraded by MAO-A. Fine-
tuning of the postsynaptic response to the release of 5-HT
is achieved through a host of different receptors and cells
and/or brain area-specific receptor profiles, thereby facilitat-
ing the different roles that 5-HT plays in physiological and
behavioural functions.
Serotonergic cell bodies are located in the raphe nuclei,
a cluster of nuclei in the brain stem projecting to almost all
brain regions(15), including lateral cortical regions, the
amygdala and the hypothalamus, which are all involved in
processing emotions and stress. Because TpH2, 5-HTT and
MAO-A are expressed in these and other brain areas(16–18),
agents acting through TpH2, 5-HTT and MAO-A will have
a global effect on 5-HT neurotransmission.
Although the precise role of 5-HT in mood disorders such
as depression, obsessive-compulsive disorder and anxiety is
not fully understood, it is evident that the 5-HT system is per-
turbed in these disorders. The synthesis, release, reuptake
and/or metabolism of 5-HT(19,20), as well as the functionality
of the 5-HT1A and 5-HT2 serotonin receptors
(21,22), are to
different extents affected in anxiety and depression. The
general view is that there is an inverse relationship between
depression and 5-HT levels, based on the antidepressive
properties of serotonin-enhancing drugs(23). In terms of
food, a positive association between the consumption of
maize, which contains less Trp compared with other food
staples, and homicide rates has been found(24). Moreover,
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another cross-national study revealed a negative correlation
between dietary Trp and suicide rates(25).
There is also evidence that genetic variation in the sero-
tonergic system increases vulnerability to anxiety- and
depression-related disorders(26–29). A common polymorph-
ism in the promoter region of the 5-HTT (SLC6A4) gene
(abbreviated: 5-HTTLPR; serotonin-transporter-linked
polymorphic region) is associated with trait anxiety(30),
and in the context of (early-life) stress, this polymorphism
increases risk for depression(31). Paradoxically, it is the
low-activity short (s) allelic variant that increases
vulnerability. Although human studies could not provide
evidence, studies employing 5-HTT knockout mice and
rats have revealed that reduced 5-HTT expression is associ-
ated with increased synaptic 5-HT levels(32). Hence, whereas
SSRI-induced increases in 5-HT levels reduce depressive
symptoms, genetically induced constitutive high 5-HT
levels appear to increase these symptoms. Furthermore,
whereas 5-HTTLPR s-allele carriers are at risk for depression
if exposed to stress, those that are depressed suffer from
decreased responsivity to SSRI. Intuitively, decreased
5-HTT expression leaves a smaller window of opportunity
for SSRI to exert their maximum effects.
In 1998, gene mapping of the X-chromosomal MAO-A
gene revealed a functional polymorphism in the upstream
promoter region, consisting of a variable number of
tandem repeats (u-VNTR). The different lengths of these
variants was found to influence protein transcription and
thus enzymic activity(33). Others linked the alleles which
confer high enzymic activity (three, four and five repeats)
to several anxiety- and depression-related disorders(34–37),
as well as reduced responsiveness to antidepressant
treatment(37,38).
Finally a number of different TpH2 SNP have been
reported in several ethnical cohorts which are thought to
cause, through either lower enzymic activity or loss of
function, lower extracellular 5-HT levels. Zhang et al.(39)
showed that an 80 % loss of function TpH2 G1463A SNP
found in a geriatric sample in North Carolina (USA) was
more prevalent in the cohort diagnosed with unipolar
depression compared with the matching control cohort.
Another study revealed in Taiwanese Han Chinese subjects
a possible association between bipolar disorder and TpH2
C2755A, which leads to a reduction of 5-HT synthesis when
expressed in cells(40), and TpH2 Pro206Ser (conferring a
30 % reduction in enzymic activity) was found to be signifi-
cantly higher expressed in a cohort of German patients
suffering from bipolar disorder compared with controls(41).
In addition to these SNP, the study on Taiwanese Han
Chinese also reported that the 2703G/2473A haplotype
(a TpH2 promoter variant associated with bipolar disorder)
resulted in reduced transcription of the TpH2 gene as well
as reduced affinity for the transcription factor POU3F2(40).
Because 5-HTT, Thp2 and/or MAO-A polymorphisms
affect the functioning of the serotonergic system, it is to
be expected that they influence the effects of serotonergic
food components, either through reduced capacity to con-
vert Trp into 5-HT (due to reduced TpH2 function),
reduced sensitivity of the serotonergic system to elevated
5-HT levels (due to reduced 5-HTT function) or enhanced
degradation of 5-HT (due to elevated MAO-A activity).
Tryptophan
Since 5-HT cannot cross the blood–brain barrier due to its
hydrophilic properties the synthesis of the neurotransmitter
takes place in the axon terminals of serotonergic neurons.
The precursor Trp is absorbed from food into the blood-
stream. When a meal containing protein is consumed a
large proportion of Trp entering the portal vein is metab-
olised in the liver, which does not happen with the other
large neutral amino acids (LNAA)(42). Thus the amount of
Trp entering the circulation is much less compared with
other LNAA, if the amounts consumed are the same. How-
ever, the secretion of insulin in response to the intake of
carbohydrates in the meal reduces the plasma concen-
trations of all LNAA except Trp, which binds to albumin
and thereby can circulate throughout the body(43,44).
Whether a meal increases the ratio of plasma Trp levels
compared with the plasma levels of other LNAA (the
TRP:LNAA ratio) depends on the amount of protein
digested and the release of insulin(45,46). When Trp in the
circulation reaches the brain capillaries it is transported
across the blood–brain barrier. Here Trp has to compete
with other LNAA for active transport across the cell
membranes of the epithelial cells lining the capillaries.
Therefore, not the plasma level of Trp alone, but the
TRP:LNAA ratio determines its rate of transport across the
blood–brain barrier(45). Once inside the brain, Trp is
taken up by the serotonergic cells of the raphe nuclei
and via two enzymic reactions it is converted into 5-HT
(see the section on the serotonergic system).
Acute tryptophan depletion
Since there is a direct relationship between dietary Trp and
brain 5-HT synthesis, the supply of 5-HT in the brain can
be exhausted by decreasing the availability of Trp. A stan-
dardised procedure to drastically decrease the levels of
5-HT is acute tryptophan depletion (ATD). In short, a
diet low in Trp is eaten by the subjects for 24 h, after
which they fast overnight and during the test day except
for a shake which contains all amino acids excluding
Trp. This in itself causes a drop in the plasma TRP:LNAA
ratio. Furthermore, protein synthesis is stimulated by the
intake of high-protein foods or drinks. A protein-rich
low-carbohydrate diet results in a decreased amount of
Trp in the brain since the TRP:LNAA ratio in normal protein
is very low. Therefore, a protein-rich low-carbohydrate diet
results in more competition for the transport system over
the blood–brain barrier and consequently less transport
of Trp into the brain. As a consequence, Trp needed for
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protein synthesis during the diet and test day must be sup-
plied by the reserves in the body. Inevitably these reserves
will be drained to the point that they cannot maintain
plasma Trp levels, causing the TRP:LNAA ratio to drop
even further, to about 15 % within 5·5 h. Brain Trp levels
drop to 5 % several hours later, which hampers brain
5-HT synthesis(47–49). The effects of ATD in healthy volun-
teers and vulnerable subjects are described in the following
sections.
Effects of acute tryptophan depletion on mood and
cognitive functions in healthy subjects
Mood. In line with the increased incidence of depression
in women, it has been reported that the mood of healthy
female volunteers but not of healthy male volunteers
dropped after ATD (about 80–90 % reduction in plasma
Trp)(50,51). In male subjects, effects of ATD on mood
were either small(52,53) or fully absent (about 70–90 %
reduction in plasma Trp)(50,51,54,55). positron emission
tomography (PET) imaging showed that there may be
differences in 5-HT synthesis and metabolism between
the sexes, which could explain the difference in response
to ATD(48). Other studies reported that the performance
of men in the Stroop Color Word Test, testing selective
attention and response inhibition, improved following
ATD (about 60–80 % reduction in plasma Trp)(56,57). How-
ever, the effects of ATD on recognition of emotional faces
are inconsistent; some observed a decrease in recognition
of facial emotions following ATD (no complete data on
plasma Trp) in women(58), others found an increase in
the recognition of happy faces by women (plasma Trp
reduced by 55 %)(59), and still others reported no effects
in both men and women following a Trp reduction of
65 %(60,61). Thus, whereas ATD impairs mood in women,
there are conflicting results concerning the effects of ATD
on the recognition of emotional faces.
Cognition. Apart from mood, ATD has been found
to affect a number of cognitive functions in healthy
individuals. Memory consolidation was impaired when
the learning of a list of words took place during the Trp-
depleted state (about 60–80 % reduction in plasma Trp),
whereas the recall of word lists learned before the ATD
procedure was not affected(56,62). Moreover, McAllister
et al.(63) showed that ATD leading to a plasma Trp
reduction of 85 % significantly impaired source memory
recall. In sum, research consistently shows memory impair-
ment following ATD.
Effects of acute tryptophan depletion on mood and
cognitive functions in vulnerable subjects
Mood. In vulnerable and subclinical subjects more
consistent evidence has been found pointing towards a
lowering of mood and alterations in cognitive functioning
in response to ATD. For instance, healthy subjects with a
multigenerational family history of affective disorders
showed a reduction in mood as measured the by the Pro-
file of Mood States scale following ATD (about 70–90 %
reduction in plasma Trp)(64,65). The same is true for
patients who are remitted from a depressive episode and
responded to SSRI treatment (Trp plasma reduced by
about 50–90 %)(66–69); however, see Leyton et al.(70). In
remitted depressed patients, ATD impaired attention to
positive stimuli (about 55–64 % reduction in plasma
Trp)(71) and decreased the recognition of fearful and
happy faces (plasma Trp reduced by 55–84 %)(59,72). Fur-
thermore, in otherwise healthy women as well as remitted
major depression patients carrying the 5-HTTLPR ss or ls
genotype it was found that ATD significantly lowered
mood compared with l-allele carriers (about 70–85 %
reduction in plasma Trp)(73–75). Interestingly, men carrying
the same genotype did not experience a lower mood, but
instead showed increased impulsivity after ATD (plasma
Trp reduced by about 75–85 %)(75,76). When ATD (77 %
reduction in plasma Trp) was combined with a stressor,
mood deteriorated even further in 5-HTTLPR ss subjects,
while no further reduction was found in individuals homo-
zygous for the l allele(77). In summary, a vulnerable seroto-
nergic system, whether due to genetic background or a
(family) history of affective disorders, seems to enhance
the mood-deteriorating effects of ATD.
Cognition. Subclinical subjects tend to suffer from
instable cognitive function, which increases the risk of cog-
nitive impairments when cognitive capacities are too low
to properly deal with environmental challenges, like
stress, but also unhealthy food. In their pooled analysis
of nine separate ATD trials, Sambeth et al.(78) discovered
that the memory impairment effect of ATD (63–97 %
reduction in plasma Trp) was more prominent in women
than in men(78). ATD (plasma Trp reduced by 69 %) also
lowered incentive motivation in 5-HTTLPR s-allele car-
riers(79). In remitted depressed patients, ATD impaired
immediate verbal recall as well as immediate and delayed
recall of lists of spoken words (plasma Trp reduced by
55–71 %)(59,80,81). However, it improved attention to neu-
tral stimuli (about 55–64 % reduction in plasma Trp)(71).
Effects of acute and (sub-)chronic tryptophan depletion
in animal models
While the behavioural effects of ATD on human subjects
are well documented, research on the effects of Trp
depletion in animal models can offer further insight into
the role of 5-HT in mood and cognitive processes and
enable researchers to examine the effects of (sub-)chronic
Trp depletion. For instance, sub-chronic Trp depletion
(SCTD) (57 % reduction in plasma Trp, prefrontal cortex
5-HT levels reduced by 34 %) in Sprague–Dawley rats
led to depression-related behaviour in the forced swim
test as well as an increase in corticosterone, aldosterone,
5-HT receptor density and increased N-methyl-D-aspartate
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(NMDA) signalling(82). In another study reward learning
was impaired without an effect on motivation, assessed
by effort discounting and reversal learning tasks, following
SCTD (no data on plasma Trp levels, ventromedial frontal
cortex 5-HT levels reduced to about 50 % of control) in
Long Evans rats(83). SCTD (no data on plasma Trp levels,
prefrontal cortex 5-HT levels reduced to 39 % of control)
in Wistar rats also resulted in enhanced proneness to
gamble and poor decision making in the rodent Iowa
Gambling Task(84). Interestingly, also in macaques per-
forming a gambling task, ATD (about 65 % reduction in
plasma Trp) increased risky decision making(85). Chronic
Trp depletion in Lister hooded rats (40–50 % reduction
of 5-HT levels in the hippocampus, frontal cortex and
striatum) impaired object recognition in the novel object-
recognition paradigm, which was reversed by administer-
ing the atypical antipsychotic risperidone(86). ATD studies
in rats have also revealed that the effects of ATD (about
50 % reduction in plasma Trp) on hippocampal and frontal
cortex 5-HT levels were more pronounced in homozygous
serotonin transporter knockout Wistar rats compared with
heterozygous knockout rats and wild-type controls(87).
Finally, the circadian rhythm of locomotor activity as well
as the sleep–wake cycle were found to be disturbed in
Sprague–Dawley rats by ATD (99 % reduction in plasma
Trp, 85 % decrease in 5-HT brain levels)(88). In conclusion,
animal studies have provided evidence that Trp depletion
indeed lowers 5-HT levels in brain areas that are involved
in several cognitive functions and mood, thus reinforcing
the conclusions drawn from human ATD studies and
providing further insight into the underlying processes.
However, some care should be taken when reviewing
these studies on Trp depletion in rats, as not all strains
respond in the same manner to Trp depletion(89).
Summary of acute tryptophan depletion
In healthy subjects the negative effects of ATD on memory
are the most profound, while it seems to enhance selective
attention and inhibition of response. Interestingly, the low-
ering of mood by ATD in healthy subjects is only consistently
found in females. This sex effect may be a consequence of
lower 5-HT synthesis in females than in males(48), making
females more vulnerable to manipulation of the serotonergic
system. This is also true for subjects that have a vulnerable
serotonergic system as a result of genetic or (family) history
of affective disorder, as is seen in the enhanced lowering of
mood and negative effects on several cognitive functions in
these vulnerable subpopulations.
Acute tryptophan supplementation
Whereas consumption of a high-protein low-carbohydrate
diet lowers Trp levels(90), consumption of a diet high in
carbohydrates increases the Trp:LNNA ratio in blood
and the brain(44,91). The intake of a high amount of
carbohydrates triggers the release of insulin that in turn
stimulates the uptake of LNAA into muscle tissue, with
the exception of Trp, which is loosely bound by free albu-
min. Combined with a low intake of protein, the plasma
TRP:LNAA ratio shifts in favour of Trp and therefore
increases the transport of Trp over the blood–brain barrier.
This method, however, only mildly elevates Trp levels in
the brain, rarely exceeding an elevation of 25 % over base-
line. Furthermore, most typical diets high in carbohydrates
are high in protein as well, negating their effect on
plasma Trp levels(92). A valid alternative is the adminis-
tration of pure Trp via intravenous injection in which the
precise elevation of pure Trp levels can be observed.
This method, however, proves to be quite invasive and
inconvenient as a regular event. Yet another approach is
oral administration of a drink high in a-lactalbumin
retrieved from whey which is high in Trp(7) and therefore
can increase plasma Trp without increasing the amount
of competing LNAA. In several studies, a-lactalbumin was
administered as a chocolate-flavoured drink; thus this
method is much more feasible for a continued adminis-
tration and even rather pleasant for the test subject,
although the increase in Trp via this method is limited
and significantly lower than via intravenous injection(93,94).
More recently hydrolysed protein and egg protein hydroly-
sate in the form of a sweetened drink have been found to
raise brain Trp up to 255 %, so oral administration does not
necessarily produce a smaller increase in plasma Trp than
pure intravenous injections(8,9). Independent of the
method, an increased amount of Trp in the brain results
directly in an increase in 5-HT synthesis since the rate-
limiting enzyme TpH2 is only half saturated under
normal circumstances and 5-HTP aromatic L-amino acid
decarboxylase is a highly active enzyme(9).
In the last decades, there have been many studies on the
effects of acute Trp supplementation (ATS) on mood and
cognition, utilising either amino acid drinks containing
pure Trp, a-lactalbumin, hydrolysed protein or egg protein
hydrolysate. Because there is no standardised protocol for
ATS, the obtained Trp:LNAA levels after digestion of the
ATS mixture or diet can differ greatly between studies.
Nonetheless, significant effects of ATS have been observed
in both healthy and (sub)clinical populations. In the next
sections modulation of various cognitive functions and
mood by ATS in healthy and vulnerable subjects will be
discussed.
Effects of acute tryptophan supplementation on mood
and cognitive functions in healthy subjects
Mood. ATS seems to modulate emotional processing in
healthy subjects, in a dose-dependent manner. An oral
dose of 1·8 g Trp (600 % increase in TRP:LNAA) increased
the recognition of fearful and happy faces in females(95).
Murphy et al.(96) found increased recognition of happy
facial expressions, and a decreased recognition of
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expressions of disgust after 14 d of 3 g Trp/d (no data on
TRP:LNAA ratio) in healthy female subjects. In another
study, drinks containing a hydrolysed egg-white protein,
which increases plasma TRP:LNAA by 191–255 %,
improved mood(9). However, carbohydrate-rich protein-
poor diets or drinks containing a-lactalbumin that increase
plasma TRP:LNAA by 21–67 % did not have an effect on
mood(9,93,97–100). Furthermore, unphysiologically high
increases in TRP:LNAA ratios negatively affected mood,
as was reported after an intravenous injection of 7 g pure
Trp (1500 % increase in TRP:LNAA)(101,102). Thus, there
may be an inverted U-shaped relationship between
TRP:LNAA ratios and mood in healthy subjects.
Cognition. Considering that memory consolidation and
recall are impaired after ATD and in depression(56,62,63),
ATS may enhance these cognitive functions. Indeed, it
has been reported that an increase of 21 % in TRP:LNAA
following the administration of two a-lactalbumin-rich
drinks improved abstract visual memory in healthy
subjects(100). However, Sobczak et al.(102) found that an
intravenous injection of 7 g Trp had an adverse effect on
performance in memory tests. Given that extreme elevation
of TRP:LNAA (1500 %) caused significant sedation in the
test subjects(102,103), these detrimental effects could well
be due to sedation and not a direct effect of increased
5-HT levels. For instance, ATS (770 % increase in plasma
free Trp, no data on TRP:LNAA ratio) has been found
to increase reaction times(96,104) and subjective fatigue(105)
in both healthy subpopulations. Thus, ATS-induced
TRP:LNAA increases of 21–43 % have beneficial effects
on memory functions, whereas higher increases impair
memory, potentially due to sedative effects.
Effects of acute tryptophan supplementation on mood and
cognitive functions in vulnerable subjects
Mood. In contrast to ATS effects on mood in healthy sub-
jects, an increase in the plasma TRP:LNAA ratio of 41–48 %
following ATS was sufficient to improve mood as well as
vigor in high-stress-vulnerable subjects undergoing labora-
tory stress(93,97). Other studies found that in women with
premenstrual complaints, ATS (29 % increase in Trp:LNAA)
improved mood during the premenstrual stage(106,107). Fur-
thermore, in 5-HTTLPR s-allele, but not l-allele, carriers,
ATS (increase in plasma TRP:LNAA of 190 %) was found
to have positive effects on mood and vigor after exposure
to laboratory stress(108). It has also been reported that ATS
(no data on TRP:LNAA levels) was without effect on mood
in 5-HTTLPR s- and l-allele carriers, but lowered hypothala-
mic–pituitary–adrenal axis activity in individuals being
homozygous for the s allele(109). In addition, ATS reduced
food intake in dieting females regardless of their
5-HTTLPR genotype, while increasing mood and emotional
eating solely in l/l subjects (plasma TRP:LNAA ratio
increased by 70 %)(110). However, it has also been demon-
strated that an a-lactalbumin-enhanced diet (21 % increase
in TRP:LNAA) failed to modulate mood or vigor in recov-
ered depressed subjects(98,100), and an increase of 21 % in
TRP:LNAA following the administration of two a-lactalbu-
min-rich drinks had no effect on mood in recovered
depressed patients(100). Perhaps these TRP:LNAA ratios of
about 20 % are too low to improve mood in vulnerable
subjects. Overall, ATS seems to have more profound effects
on mood in vulnerable populations than in healthy sub-
jects. Potentially, factors such as lower baseline levels of
5-HT and reduced capacity to clear released 5-HT from
the synaptic cleft may help to clarify whether ATS has ben-
eficial effects in individuals with mood disturbances.
Cognition. An increase of 21 % in TRP:LNAA following
the administration of two a-lactalbumin-rich drinks
improved abstract visual memory in both healthy controls
and recovered depressed patients(100). Another study
found that in women with premenstrual complaints, ATS
improved memory for abstract figures (29 % increase in
TRP:LNAA) and word recognition (6–25 % increase in
TRP:LNAA) during the premenstrual stage(106,107). Further-
more, Markus et al.(111) reported an enhanced short-term
memory scanning in healthy high-stress-prone subjects
following laboratory stress and after consumption of a
high-carbohydrate low-protein diet (TRP:LNAA ratio
increased by 42 %) or after consumption of a diet enriched
with a-lactalbumin (Trp:LNAA ratio increased by 43 %)(112).
Together these data suggest that also in vulnerable subjects
ATS improves memory-related processes, at rather low
increases in plasma TRP:LNAA ratios. As to whether the
high Trp-induced sedative effects on cognition as observed
in healthy subjects also take place in vulnerable subjects
needs to be investigated.
Effects of acute and (sub-)chronic tryptophan
supplementation in animal models
As in the case of Trp depletion, the added value of study-
ing Trp supplementation in animals lies in the ability to
provide direct 5-HT level read-outs from the whole brain
or specific brain areas and assess (sub-)chronic effects of
Trp supplementation. Feurte´ et al.(113) showed that chronic
supplementation of the diet of rats with a-lactalbumin
leads to a stable increase of 40 % in plasma TRP:LNAA.
Increasing plasma TRP:LNAA levels in rats were found
to increase brain 5-HT levels, as dietary sub-chronic Trp
supplementation (30 % increase in brain TRP:LNAA) in
Sprague–Dawley rats resulted in an increase of 92 % in
extracellular 5-HT levels in the dorsal hippocampus. More-
over, the effect of the 5-HT-releasing agent fenfluramine
was enhanced as was performance in a differential
reinforcement of low rate responding condition (mimick-
ing SSRI treatment)(114). Collins et al.(115) showed that
supplementation of an egg white protein hydrolysate
replenished brain serotonin stores, even after pharmaco-
logical depletion of serotonin from the brain by 3,4-methy-
lenedioxymethamphetamine(115). In Wistar rats chronic
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treatment with Trp by oral administration (about 60 %
increase in plasma Trp:LNAA) was shown to increase
5-HT levels in the hippocampus by 57 %, in the cortex by
46 % and by 72 % in the rest of the brain, as well as boost-
ing performance in the radial arm maze test and water
maze test, indicating improvement in both short- and
long-term memory(116,117). However, a 7 d Trp treatment
in mice suppressed food intake significantly and, more
worryingly, increased brain thiobarbituric acid-reactive
substances (a measure for oxidative stress)(118). Taken
together, these data show that it might be worthwhile to
investigate whether the positive effects of ATS in human
subjects could be maintained when diet is supplemented
with Trp over a longer period of time. Although some
care should be taken, the increase in oxidative stress fol-
lowing chronic Trp supplementation in mice should not
be taken lightly.
Summary of acute tryptophan supplementation
ATS seems to improve mood and cognition in both healthy
and vulnerable subjects. Effects of ATS on cognition are
more consistent and require lower increases in the
plasma TRP:LNAA ratios than needed to improve mood.
Yet, for both mood and cognition it has been shown that
too high increases in Trp levels result in poorer perform-
ances. As serotonin synthesis can theoretically only be
increased to a maximum of 200 % due to saturation of
TpH2 (see the acute tryptophan supplementation section),
it is not likely that the poor performance results from
local negative responses to elevated serotonin levels like
sensitisation. However, a possible explanation could be
sedation, which was reported in one study(105), caused
by the subsequent synthesis of melatonin from serotonin
by serotonin-N-acetyltransferase and hydroxyindole-O-
methyltransferase(119). Taken together, these data suggest
that there is an inverted U-shaped curve for plasma
Trp levels and mood/cognition. Finally, research in
animal models has provided results that seem to justify
further investigation of chronic Trp supplementation in
human subjects.
Triple monoamine inhibitors
Unbeknownst to the individuals of ancient and medieval
times, some of the medicinal herbs they used actually con-
tained monoamine reuptake transporter inhibitors. During
the previous decade a number of studies focused on the
antidepressant-like effects of extracts from several subspe-
cies of St John’s wort (Hypericum perfoliatum), which was
traditionally used to treat wounds, eczema and disorders of
the central nervous system(120). Not only did these studies
reveal replicable antidepressant effects in mice(121–124),
analysis of monoamine uptake by rat synaptosomes
showed that uptake of all three monoamines was inhibited
by these extracts(121,124). In addition to St John’s wort, the
presence of monoamine reuptake inhibitors was shown
in the extracts of Siphocampylus verticillatus (a Brazilian
medicinal plant)(125), in Fructus Akebiae (a traditional
Chinese cure for depressive disorders)(126) and Sideritis
scardica (used as a tea, flavouring agent and universal
remedy around the Mediterranean)(127).
Perhaps even more surprising is the presence of mono-
amine transporter inhibitors in regular foods. In 2003, a
group of researchers reported on a group of isoflavans
and isoflavenes, which are present in licorice, with seroto-
nin transporter (SERT)-inhibiting properties(128). After 7 d
of oral injections with the extract of the roots of Glycyr-
rhiza glabra (from which licorice is made), mice showed
enhanced learning and memory performance in the
passive avoidance paradigm and reduced anxiety in the
elevated plus maze(129), as well as reduced immobility
in the forced swim and tail suspension tests for
depression(130). These findings suggest that the extract
from G. glabra possesses antidepressant potentials.
Recently, Mechan et al.(12) demonstrated that a supercritical
CO2 oregano extract acting as a moderate noradrenaline,
serotonin and dopamine reuptake inhibitor and MAO
inhibitor exerted antidepressant-like and anxiolytic effects
in mice. In the same study, the researchers used in vivo
microdialysis in rats to confirm that extracellular 5-HT
levels were indeed higher after a dose of the oregano
extract, albeit more slightly compared with the antidepress-
ant fluoxetine. Moreover, electroencephalogram measure-
ments after acute oral supplementation in freely moving
rats showed that this extract may exhibit antidepressant
and neuroprotective activities(131). Taken together, the
results of these studies seem to justify further investigation
into possible other dietary sources of monoamine reuptake
inhibitors, as well as studies testing whether the beneficial
behavioural effects of these plant extracts found in mice
can be replicated in human subjects. An important fact to
note is that the half maximal inhibitory concentration
(IC50s) of these plant-derived monoamine reuptake inhibi-
tors are about 1000-fold lower than those of pharmacologi-
cal compounds, making the chances of detrimental side
effects much lower(12). In addition, a recent study investi-
gating the attitudes of the general public and general prac-
titioners towards enhancement of mood and cognition in
healthy individuals by either pharmaceuticals or natural
compounds showed that the public, especially, tends to
be more favourable towards natural compounds(132).
Summary and conclusion
While the serotonergic system is an important target for
many pharmacological agents applied in psychiatry, this
system is also amenable to influences of food. Indeed,
food containing a low TRP:LNAA ratio tends to reduce
mood and cognition, and food that increases this ratio
may increase mood and cognition in humans. However,
as we reviewed, the relationship between Trp intake and
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behavioural performance is not unequivocal. In part this is
because methods that have been used to lower or increase
the plasma TRP:LNAA ratio differ considerably across
studies. Nonetheless, there may be an inverted U-shaped
relationship between central 5-HT levels and optimal
mood/cognition; low and too high Trp levels impair
mood/cognition, and moderate to high Trp levels
improve mood/cognition. Regarding cognition this
relationship is found for both healthy and vulnerable sub-
jects (Fig. 1(a)). However, regarding mood, effects of ATD
and ATS seem to depend on the functioning of the
serotonergic system of vulnerable or subclinical subjects,
with a much more profound decrease in mood of vulner-
able subjects compared with healthy subjects in the
lower brain Trp range (Fig. 1(b)). However, if brain Trp
levels are in the optimum range, mood in vulnerable sub-
jects is comparable with mood in healthy subjects. In
healthy individuals an increase in plasma TRP:LNAA of
67 % does not modulate mood, while in vulnerable subjects
an increase of 20–50 % is sufficient to normalise their brain
Trp levels and thus produce positive effects on mood. Such
positive effects on mood are only seen in healthy subjects
following a 191–255 % increase in plasma TRP:LNAA
levels. When plasma Trp levels are elevated beyond that
range, mood in both healthy and vulnerable subjects is
negatively affected. Given that Western and new world
societies are increasingly demanding and food is generally
abundantly available in these societies, insight in beneficial
TRP:LNAA ratios in food for specific target groups may
help the nutrition industry to adapt food to support our
mood and cognition.
One group of individuals that is vulnerable to manipula-
tions of the serotonergic system is the one that carries the s
allele of the 5-HTTLPR polymorphism. Studies employing
5-HTT knockout mice and rats as a model have revealed
that reduced 5-HTT expression (as hypothesised for
5-HTTLPR s-allele carriers) is associated with increased extra-
cellular 5-HT levels, reduced intra-neuronal 5-HT levels
and increased 5-HT synthesis. Also, various 5-HT receptors
are down-regulated(32). As to whether Trp levels or its
transport over the blood–brain barrier is affected by the
5-HTTLPR genotype is unknown to date. Nonetheless, if
5-HT synthesis is enhanced to compensate lower 5-HT
tissue levels, it may not be surprising that 5-HTTLPR
s-allele carriers are more sensitive to Trp depletion(74), an
effect that has also been observed in 5-HTT knockout
rats(87). In contrast to ATD, ATS has a positive effect on
mood, vigor and cortisol response after exposure to labora-
tory stress in ss subjects(108,109). 5-HTTLPR s-allele carriers
are more sensitive to stress(133) and are more prone to
develop depression after adverse life events(31). Given
that ATS has been reported to dampen the negative effects
on mood invoked by stress(108,109), it is of interest to
test whether (chronic) ATS improves stress coping and
decreases risk for depression in s-allele carriers. Finally,
to date, no studies on the effects of chronic Trp
supplementation in human subjects have been conducted.
With the recent discovery of powerful tools for enhancing
available Trp through diet, such as hydrolysed protein or
egg protein hydrolysate(8,9), and promising data from ATS
studies, chronic Trp supplementation studies in human
subjects are warranted. Ultimately, enhancing available
Trp in food such as cereals, maize and milk formulas
may represent an efficient and cost-effective way of

























Fig. 1. Relationship between brain tryptophan (Trp) levels and cognition/
mood. In both healthy and vulnerable subjects too low and too high brain Trp
levels result in impaired cognitive ability. This indicates that in the case of cog-
nition, brain Trp levels should lie within an optimum range (a). The effects of
small increases or decreases in brain Trp levels on the mood of healthy sub-
jects is negligible (b, ). Only large increases in brain Trp levels are able to
improve mood significantly in these subjects. Conversely, in vulnerable sub-
jects (b, ) relatively small increases in brain Trp result in an improved
mood. Unphysiologically high increases in brain Trp lead to negative effects
on mood in both healthy and vulnerable subjects. (A colour version of this
figure can be found online at http://www.journals.cambridge.org/nrr)
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well-being in the current increasingly demanding society.
Specifically, insight into beneficial Trp:LNAA ratios in
food for specific target groups – as presented here –
may help the nutrition industry to increase the functionality
of our food. Specifically, contrary to popular belief, most
common foods high in Trp do not increase the plasma
TRP:LNAA ratio enough to exert any positive effects on
mood/cognition, because they also contain large amounts
of other LNAA. Hence, functional foods have to be
designed containing much higher levels of Trp compared
with other LNAA. With about 10 % of the population over
12 years of age taking antidepressants in the USA
alone(134) and the numerous side effects associated with
their use, consumption of these functional foods to prevent
depression in the first place is alluring for both clinicians
and the general public.
Acknowledgements
J. R. H. is financially supported by The Netherlands Organ-
isation for Scientific Research (NWO), grant no. 86410003.
NWO had no further role in the design of the study, in the
collection, analysis and interpretation of data, in the writing
of the report, and in the decision to submit the paper for
publication.
S. H., A. M., M. H. M. and J. R. H. wrote the manuscript,
S. H. organised the references and made the figures, J. R. H.
designed the manuscript, and J. R. H. and M. H. M.
together wrote the conclusions.
There are no conflicts of interest.
References
1. American Psychiatric Association (1994) Diagnostic and
Statistical Manual of Mental Disorders, 4th ed. Washington,
DC: American Psychiatric Association.
2. Olivier B, Chan JS, Snoeren EM, et al. (2011) Differences
in sexual behaviour in male and female rodents: role of
serotonin. Curr Top Behav Neurosci 8, 15–36.
3. Wurtman RJ, Hefti F & Melamed E (1980) Precursor control
of neurotransmitter synthesis. Pharmacol Rev 32, 315–335.
4. Kerem Z, Lev-Yadun S, Gopher A, et al. (2007) Chickpea
domestication in the Neolithic Levant through the nutri-
tional perspective. J Archaeol Sci 34, 1289–1293.
5. Katz SH, Hediger ML & Valleroy LA (1974) Traditional maize
processing techniques in the new world. Science 184,
765–773.
6. Morris CE & Sands DC (2006) The breeder’s dilemma –
yield or nutrition? Nature Biotechnol 24, 1078–1080.
7. Heine W, Radke M, Wutzke KD, et al. (1996) a-Lactalbu-
min-enriched low-protein infant formulas: a comparison
to breast milk feeding. Acta Paediatr 85, 1024–1028.
8. Mitchell ES, Slettenaar M, Quadt F, et al. (2011) Effect of
hydrolysed egg protein on brain tryptophan availability.
Br J Nutr 105, 611–617.
9. Markus CR, Firk C, Gerhardt C, et al. (2008) Effect of differ-
ent tryptophan sources on amino acids availability to the
brain and mood in healthy volunteers. Psychopharma-
cology 201, 107–114.
10. Silber BY & Schmitt JAJ (2010) Effects of tryptophan loading
on human cognition, mood, and sleep. Neurosci Biobehav
Rev 34, 387–407.
11. Booij L, Van der Does AJ & Riedel WJ (2003) Monoamine
depletion in psychiatric and healthy populations: review.
Mol Psychiatry 8, 951–973.
12. Mechan AO, Fowler A, Seifert N, et al. (2011) Monoamine
reuptake inhibition and mood-enhancing potential of a
specified oregano extract. Br J Nutr 105, 1150–1163.
13. Kroeze Y, Zhou H & Homberg JR (2012) The genetics of
selective serotonin reuptake inhibitors. Pharmacol Ther
136, 375–400.
14. Neal KB, Parry LJ & Bornstein JC (2009) Strain-specific gen-
etics, anatomy and function of enteric neural serotonergic
pathways in inbred mice. J Physiol 587, 567–586.
15. Azmitia EC & Whitaker-Azmitia PM (1995) Anatomy, cell
biology and plasticity of the serotonergic system. In Psycho-
pharmacology: The Fourth Generation of Progress, pp.
443–449 [FE Bloom and DJ Kupfer, editors]. New York:
Raven Press.
16. Gutknecht L, Kriegebaum C, Waider J, et al. (2009) Spatio-
temporal expression of tryptophan hydroxylase isoforms in
murine and human brain: convergent data from Tph2
knockout mice. Eur Neuropsychopharmacol 19, 266–282.
17. Saura J, Andre´s N, Andrade C, et al. (1997) Biphasic and
region-specific MAO-B response to aging in normal
human brain. Neurobiol Aging 18, 497–507.
18. Torres GE, Gainetdinov RR & Caron MG (2003) Plasma
membrane monoamine transporters: structure, regulation
and function. Nat Rev Neurosci 4, 13–25.
19. Van Praag HM, Korf J & Puite J (1970) 5-Hydroxyindoleace-
tic acid levels in the cerebrospinal fluid of depressive
patients treated with probenecid. Nature 225, 1259–1260.
20. Malison RT, Price LH, Berman R, et al. (1998) Reduced
brain serotonin transporter availability in major depression
as measured by [123I]-2b-carbomethoxy-3b-(4-iodophenyl)-
tropane and single photon emission computed tomogra-
phy. Biol Psychiatry 44, 1090–1098.
21. Cowen PJ, Power AC, Ware CJ, et al. (1994) 5-HT1A recep-
tor sensitivity in major depression. A neuroendocrine study
with buspirone. Br J Psychiatry 164, 372–379.
22. Sargent PA, Kjaer KH, Bench CJ, et al. (2000) Brain seroto-
nin 1A receptor binding measured by positron emission
tomography with [11C]WAY-100635: effects of depression
and antidepressant treatment. Arch Gen Psychiatry 57,
174–180.
23. Nutt DJ (2002) The neuropharmacology of serotonin and
noradrenaline in depression. Int Clin Psychopharmacol
17, S1–S12.
24. Mawson AR & Jacobs KW (1978) Corn consumption, trypto-
phan, and cross-national homicide rates. J Orthomol
Psychiatry 7, 227–230.
25. Voracek M & Tran US (2007) Dietary tryptophan intake and
suicide rate in industrialized nations. J Affect Disord 98,
259–262.
26. Gordon JA & Hen R (2004) The serotonergic system and
anxiety. Neuromolecular Med 5, 27–40.
27. McDougle CJ, Epperson CN, Price LH, et al. (1998)
Evidence for linkage disequilibrium between serotonin
transporter protein gene (SLC6A4) and obsessive compul-
sive disorder. Mol Psychiatry 3, 270–273.
28. van Praag HM (2004) Can stress cause depression? Prog
Neuropsychopharmacol Biol Psychiatry 28, 891–907.
29. Maes M & Meltzer H (1995) The serotonin hypothesis of
major depression. In Psychopharmacology: The Fourth
Generation of Progress, pp. 933–944 [FE Bloom and
DJ Kupfer, editors]. New York: Raven Press.

















Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:48:22, subject to the Cambridge Core terms of use, available at
30. Lesch K-P, Bengel D, Heils A, et al. (1996) Association of
anxiety-related traits with a polymorphism in the serotonin
transporter gene regulatory region. Science 274,
1527–1531.
31. Caspi A, Sugden K, Moffitt TE, et al. (2003) Influence of life
stress on depression: moderation by a polymorphism in the
5-HTT gene. Science 301, 386–389.
32. Kalueff AV, Olivier JD, Nonkes LJ, et al. (2010) Conserved
role for the serotonin transporter gene in rat and mouse
neurobehavioral endophenotypes. Neurosci Biobehav Rev
34, 373–386.
33. Sabol SZ, Hu S & Hamer D (1998) A functional polymorph-
ism in the monoamine oxidase A gene promoter. Hum
Genet 103, 273–279.
34. Deckert J, Catalano M, Syagailo YV, et al. (1999) Excess of
high activity monoamine oxidase A gene promoter alleles
in female patients with panic disorder. Hum Mol Genet 8,
621–624.
35. Ni X, Sicard T, Bulgin N, et al. (2007) Monoamine oxidase A
gene is associated with borderline personality disorder.
Psychiatr Genet 17, 153–157.
36. Schulze TG, Mu¨ller DJ, Krauss H, et al. (2000) Association
between a functional polymorphism in the monoamine
oxidase A gene promoter and major depressive disorder.
Am J Med Genet 96, 801–803.
37. Yu YW, Tsai SJ & Hong CJ (2005) Association study of a
monoamine oxidase A gene promoter polymorphism with
major depressive disorder and antidepressant response.
Neuropsychopharmacology 30, 1719–1723.
38. Domschke K, Braun M, Ohrmann P, et al. (2006) Associ-
ation of the functional 21019C/G 5-HT1A polymorphism
with prefrontal cortex and amygdala activation measured
with 3 T fMRI in panic disorder. Int J Neuropsychopharma-
col 9, 349–355.
39. Zhang X, Gainetdinov RR, Beaulieu J-M, et al. (2005)
Loss-of-function mutation in tryptophan hydroxylase-2
identified in unipolar major depression. Neuron 45, 11–16.
40. Lin YM, Chao SC, Chen TM, et al. (2007) Association of
functional polymorphisms of the human tryptophan
hydroxylase 2 gene with risk for bipolar disorder in Han
chinese. Arch Gen Psychiatry 64, 1015–1024.
41. Cichon S, Winge I, Mattheisen M, et al. (2008) Brain-
specific tryptophan hydroxylase 2 (TPH2): a functional
Pro206Ser substitution and variation in the 50-region are
associated with bipolar affective disorder. Hum Mol Genet
17, 87–97.
42. Ross DS, Fernstrom JD & Wurtman RJ (1973) The role of
dietary protein in generating daily rhythms in rat liver
tryptophan pyrrolase and tyrosine transaminase. Metab-
olism 22, 1175–1184.
43. Yuwiler A, Oldendorf WH, Geller E, et al. (1977) Effect of
albumin binding and amino acid competition on trypto-
phan uptake into brain. J Neurochem 28, 1015–1023.
44. Fernstrom JD, Larin F & Wurtman RJ (1973) Correlation
between brain tryptophan and plasma neutral amino acid
levels following food consumption in rats. Life Sci 13,
517–524.
45. Fernstrom JD & Wurtman RJ (1972) Brain serotonin content:
physiological regulation by plasma neutral amino acids.
Science 178, 414–416.
46. Fernstrom JD & Faller DV (1978) Neutral amino acids in the
brain: changes in response to food ingestion. J Neurochem
30, 1531–1538.
47. Carpenter LL, Anderson GM, Pelton GH, et al. (1998)
Tryptophan depletion during continuous CSF sampling in
healthy human subjects. Neuropsychopharmacology 19,
26–35.
48. Nishizawa S, Benkelfat C, Young SN, et al. (1997)
Differences between males and females in rates of seroto-
nin synthesis in human brain. Proc Natl Acad Sci U S A
94, 5308–5313.
49. Williams WA, Shoaf SE, Hommer D, et al. (1999) Effects of
acute tryptophan depletion on plasma and cerebrospinal
fluid tryptophan and 5-hydroxyindoleacetic acid in
normal volunteers. J Neurochem 72, 1641–1647.
50. Ellenbogen MA, Young SN, Dean P, et al. (1996) Mood
response to acute tryptophan depletion in healthy volun-
teers: sex differences and temporal stability. Neuropsycho-
pharmacology 15, 465–474.
51. Smith KA, Clifford EM, Hockney RA, et al. (1997) Effect of
tryptophan depletion on mood in male and female volun-
teers: a pilot study. Hum Psychopharmacol 12, 111–117.
52. Smith SE, Pihl RO, Young SN, et al. (1987) A test of possible
cognitive and environmental influences on the mood
lowering effect of tryptophan depletion in normal males.
Psychopharmacology 91, 451–457.
53. Young SN, Smith SE, Pihl RO, et al. (1985) Tryptophan
depletion causes a rapid lowering of mood in normal
males. Psychopharmacology 87, 173–177.
54. Abbott FV, Etienne P, Franklin KBJ, et al. (1992) Acute
tryptophan depletion blocks morphine analgesia in the
cold-pressor test in humans. Psychopharmacology 108,
60–66.
55. Danjou P, Hamon M, Lacomblez L, et al. (1990) Psychomo-
tor, subjective and neuroendocrine effects of acute trypto-
phan depletion in the healthy volunteer. Psychiat
Psychobiol 5, 31–38.
56. Schmitt JA, Jorissen BL, Sobczak S, et al. (2000) Tryptophan
depletion impairs memory consolidation but improves
focussed attention in healthy young volunteers. J Psycho-
pharmacol 14, 21–29.
57. Scholes KE, Harrison BJ, O’Neill BV, et al. (2006) Acute
serotonin and dopamine depletion improves attentional
control: findings from the Stroop task. Neuropsychophar-
macology 32, 1600–1610.
58. Harmer CJ, Rogers RD, Tunbridge E, et al. (2003) Trypto-
phan depletion decreases the recognition of fear in
female volunteers. Psychopharmacology 167, 411–417.
59. Hayward G, Goodwin GM, Cowen PJ, et al. (2005) Low-
dose tryptophan depletion in recovered depressed patients
induces changes in cognitive processing without depressive
symptoms. Biol Psychiatry 57, 517–524.
60. Van Der Veen FM, Evers EAT, Deutz NEP, et al. (2007)
Effects of acute tryptophan depletion on mood and facial
emotion perception related brain activation and perform-
ance in healthy women with and without a family history
of depression. Neuropsychopharmacology 32, 216–224.
61. Cools R, Calder AJ, Lawrence AD, et al. (2005) Individual
differences in threat sensitivity predict serotonergic modu-
lation of amygdala response to fearful faces. Psychophar-
macology 180, 670–679.
62. Riedel WJ, Klaassen T, Deutz NE, et al. (1999) Tryptophan
depletion in normal volunteers produces selective impair-
ment in memory consolidation. Psychopharmacology 141,
362–369.
63. McAllister-Williams R, Massey A & Rugg M (2002) Effects of
tryptophan depletion on brain potential correlates of episo-
dic memory retrieval. Psychopharmacology 160, 434–442.
64. Benkelfat C, Ellenbogen MA, Dean P, et al. (1994)
Mood-lowering effect of tryptophan depletion. Enhanced
susceptibility in young men at genetic risk for major affec-
tive disorders. Arch Gen Psychiatry 51, 687–697.
65. Klaassen T, Riedel WJ, van Someren A, et al. (1999)
Mood effects of 24-hour tryptophan depletion in healthy

















Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:48:22, subject to the Cambridge Core terms of use, available at
first-degree relatives of patients with affective disorders.
Biol Psychiatry 46, 489–497.
66. Delgado PL, Charney DS, Price LH, et al. (1990) Serotonin
function and the mechanism of antidepressant action. Rever-
sal of antidepressant-induced remission by rapid depletion
of plasma tryptophan. Arch Gen Psychiatry 47, 411–418.
67. Delgado PL, Price LH, Miller HL, et al. (1994) Serotonin and
the neurobiology of depression. Effects of tryptophan
depletion in drug-free depressed patients. Arch Gen
Psychiatry 51, 865–874.
68. Moreno FA, Gelenberg AJ, Heninger GR, et al. (1999)
Tryptophan depletion and depressive vulnerability. Biol
Psychiatry 46, 498–505.
69. Smith KA, Fairburn CG & Cowen PJ (1999) Symptomatic
relapse in bulimia nervosa following acute tryptophan
depletion. Arch Gen Psychiatry 56, 171–176.
70. Leyton M, Young SN, Blier P, et al. (1997) The effect of
tryptophan depletion on mood in medication-free, former
patients with major affective disorder. Neuropsychopharma-
cology 16, 294–297.
71. Booij L, Van der Does AJW, Haffmans PMJ, et al. (2005) The
effects of high-dose and low-dose tryptophan depletion on
mood and cognitive functions of remitted depressed
patients. J Psychopharmacol 19, 267–275.
72. Merens W, Booij L, Haffmans PJ, et al. (2008) The effects of
experimentally lowered serotonin function on emotional
information processing and memory in remitted depressed
patients. J Psychopharmacol 22, 653–662.
73. Neumeister A, Konstantinidis A, Stastny J, et al. (2002)
Association between serotonin transporter gene promoter
polymorphism (5HTTLPR) and behavioral responses to
tryptophan depletion in healthy women with and without
family history of depression. Arch Gen Psychiatry 59,
613–620.
74. Neumeister A, Hu XZ, Luckenbaugh DA, et al. (2006)
Differential effects of 5-HTTLPR genotypes on the beha-
vioral and neural responses to tryptophan depletion in
patients with major depression and controls. Arch Gen
Psychiatry 63, 978–986.
75. Walderhaug E, Magnusson A, Neumeister A, et al. (2007)
Interactive effects of sex and 5-HTTLPR on mood and
impulsivity during tryptophan depletion in healthy
people. Biol Psychiatry 62, 593–599.
76. Walderhaug E, Herman AI, Magnusson A, et al. (2010) The
short (S) allele of the serotonin transporter polymorphism
and acute tryptophan depletion both increase impulsivity
in men. Neurosci Lett 473, 208–211.
77. Firk C & Markus CR (2009) Differential effects of 5-HTTLPR
genotypes on mood, memory, and attention bias following
acute tryptophan depletion and stress exposure. Psycho-
pharmacology 203, 805–818.
78. Sambeth A, Blokland A, Harmer CJ, et al. (2007) Sex differ-
ences in the effect of acute tryptophan depletion on
declarative episodic memory: a pooled analysis of nine
studies. Neurosci Biobehav Rev 31, 516–529.
79. Roiser JP, Blackwell AD, Cools R, et al. (2006) Serotonin
transporter polymorphism mediates vulnerability to loss
of incentive motivation following acute tryptophan
depletion. Neuropsychopharmacology 31, 2264–2272.
80. Porter RJ, Phipps AJ, Gallagher P, et al. (2005) Effects of
acute tryptophan depletion on mood and cognitive func-
tioning in older recovered depressed subjects. Am J Geriatr
Psychiatry 13, 607–615.
81. Roiser JP, Muller U, Clark L, et al. (2007) The effects of
acute tryptophan depletion and serotonin transporter
polymorphism on emotional processing in memory and
attention. Int J Neuropsychopharmacol 10, 449–461.
82. Franklin M, Bermudez I, Murck H, et al. (2012) Sub-chronic
dietary tryptophan depletion – an animal model of
depression with improved face and good construct validity.
J Psychiatr Res 46, 239–247.
83. Izquierdo A, Carlos K, Ostrander S, et al. (2012) Impaired
reward learning and intact motivation after serotonin
depletion in rats. Behav Brain Res 233, 494–499.
84. Koot S, Zoratto F, Cassano T, et al. (2012) Compromised
decision-making and increased gambling proneness follow-
ing dietary serotonin depletion in rats. Neuropharmacology
62, 1640–1650.
85. Long AB, Kuhn CM & Platt ML (2009) Serotonin shapes
risky decision making in monkeys. Soc Cogn Affect Neuro-
sci 4, 346–356.
86. Jenkins TA, Elliott JJ, Ardis TC, et al. (2010) Tryptophan
depletion impairs object-recognition memory in the rat:
reversal by risperidone. Behav Brain Res 208, 479–483.
87. Olivier JDA, Jans LAW, Korte-Bouws GAH, et al. (2008)
Acute tryptophan depletion dose dependently impairs
object memory in serotonin transporter knockout rats.
Psychopharmacology 200, 243–254.
88. Nakamaru-Ogiso E, Miyamoto H, Hamada K, et al. (2012)
Novel biochemical manipulation of brain serotonin reveals
a role of serotonin in the circadian rhythm of sleep–wake
cycles. Eur J Neurosci 35, 1762–1770.
89. Jans L, Korte-Bouws G, Korte S, et al. (2010) The effects
of acute tryptophan depletion on affective behaviour and
cognition in Brown Norway and Sprague Dawley rats.
J Psychopharmacol 24, 605–614.
90. Fernstrom JD (1990) Aromatic amino acids and monoamine
synthesis in the central nervous system: influence of the
diet. J Nutr Biochem 1, 508–517.
91. Fernstrom JD & Wurtman RJ (1971) Brain serotonin content:
increase following ingestion of carbohydrate diet. Science
174, 1023–1025.
92. Yokogoshi H & Wurtman RJ (1986) Meal composition and
plasma amino acid ratios: effect of various proteins or
carbohydrates, and of various protein concentrations.
Metabolism 35, 837–842.
93. Markus CR, Olivier B, Panhuysen GE, et al. (2000) The
bovine protein a-lactalbumin increases the plasma ratio of
tryptophan to the other large neutral amino acids, and in
vulnerable subjects raises brain serotonin activity, reduces
cortisol concentration, and improves mood under stress.
Am J Clin Nutr 71, 1536–1544.
94. Orosco M, Rouch C, Beslot F, et al. (2004) a-Lactalbumin-
enriched diets enhance serotonin release and induce anxio-
lytic and rewarding effects in the rat. Behav Brain Res 148,
1–10.
95. Attenburrow MJ, Williams C, Odontiadis J, et al. (2003) Acute
administration of nutritionally sourced tryptophan increases
fear recognition. Psychopharmacology 169, 104–107.
96. Murphy SE, Longhitano C, Ayres RE, et al. (2006) Trypto-
phan supplementation induces a positive bias in the pro-
cessing of emotional material in healthy female
volunteers. Psychopharmacology 187, 121–130.
97. Markus CR, Panhuysen G, Tuiten A, et al. (1998) Does carbo-
hydrate-rich, protein-poor food prevent a deterioration of
mood and cognitive performance of stress-prone subjects
when subjected to a stressful task? Appetite 31, 49–65.
98. Merens W, Booij L, Markus R, et al. (2005) The effects of a
diet enriched with a-lactalbumin on mood and cortisol
response in unmedicated recovered depressed subjects
and controls. Br J Nutr 94, 415–422.
99. Scrutton H, Carbonnier A, Cowen PJ, et al. (2007) Effects of
a-lactalbumin on emotional processing in healthy women.
J Psychopharmacol 21, 519–524.

















Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:48:22, subject to the Cambridge Core terms of use, available at
100. Booij L, Merens W, Markus CR, et al. (2006) Diet rich in
a-lactalbumin improves memory in unmedicated recovered
depressed patients and matched controls. J Psychopharma-
col 20, 526–535.
101. Sobczak S, Honig A, Van Duinen MA, et al. (2002) Mood,
prolactin and cortisol responses following intravenous
L-tryptophan challenge: evidence for serotonergic vulner-
ability in first-degree relatives of bipolar patients. Int J
Neuropsychopharmacol 5, 249–254.
102. Sobczak S, Honig A, Schmitt JA, et al. (2003) Pronounced cog-
nitive deficits following an intravenous L-tryptophan chal-
lenge in first-degree relatives of bipolar patients compared
to healthy controls. Neuropsychopharmacology 28, 711–719.
103. Luciana M, Burgund ED, Berman M, et al. (2001) Effects of
tryptophan loading on verbal, spatial and affective working
memory functions in healthy adults. J Psychopharmacol 15,
219–230.
104. Morgan RM, Parry AMM, Arida RM, et al. (2007) Effects of
elevated plasma tryptophan on brain activation associated
with the Stroop task. Psychopharmacology 190, 383–389.
105. Cunliffe A, Obeid OA & Powell-Tuck J (1998) A placebo
controlled investigation of the effects of tryptophan or
placebo on subjective and objective measures of fatigue.
Eur J Clin Nutr 52, 425–430.
106. Sayegh R, Schiff I, Wurtman J, et al. (1995) The effect of a
carbohydrate-rich beverage on mood, appetite, and cogni-
tive function in women with premenstrual syndrome.
Obstet Gynecol 86, 520–528.
107. Schmitt JAJ, Jorissen BL, Dye L, et al. (2005) Memory func-
tion in women with premenstrual complaints and the effect
of serotonergic stimulation by acute administration of an
a-lactalbumin protein. J Psychopharmacol 19, 375–384.
108. Markus CR & Firk C (2009) Differential effects of tri-allelic
5-HTTLPR polymorphisms in healthy subjects on mood
and stress performance after tryptophan challenge. Neuro-
psychopharmacology 34, 2667–2674.
109. Cerit H, Jans LAW & Van der Does W (2012) The effect of
tryptophan on the cortisol response to social stress is
modulated by the 5-HTTLPR genotype. Psychoneuroendo-
crinology 38, 201–208.
110. Markus CR, Verschoor E & Smeets T (2012) Differential
effect of the 5-HTT gene-linked polymorphic region on
emotional eating during stress exposure following trypto-
phan challenge. J Nutr Biochem 23, 410–416.
111. Markus CR, Panhuysen G, Jonkman LM, et al. (1999)
Carbohydrate intake improves cognitive performance of
stress-prone individuals under controllable laboratory
stress. Br J Nutr 82, 457–467.
112. Markus CR, Olivier B & de Haan EH (2002) Whey protein
rich in a-lactalbumin increases the ratio of plasma trypto-
phan to the sum of the other large neutral amino acids
and improves cognitive performance in stress-vulnerable
subjects. Am J Clin Nutr 75, 1051–1056.
113. Feurte´ S, Gerozissis K, Regnault A, et al. (2001) Plasma
Trp/LNAA ratio increases during chronic ingestion of an
a-lactalbumin diet in rats. Nutr Neurosci 4, 413–418.
114. Stelt H, Broersen L, Olivier B, et al. (2004) Effects of dietary
tryptophan variations on extracellular serotonin in the
dorsal hippocampus of rats. Psychopharmacology 172,
137–144.
115. Collins CM, Kloek J & Elliott JM (2013) Parallel changes in
serotonin levels in brain and blood following acute admin-
istration of MDMA. J Psychopharmacol 27, 109–112.
116. Haider S, Khaliq S, Ahmed SP, et al. (2006) Long-term
tryptophan administration enhances cognitive performance
and increases 5HT metabolism in the hippocampus of
female rats. Amino Acids 31, 421–425.
117. Haider S, Khaliq S & Haleem DJ (2007) Enhanced seroto-
nergic neurotransmission in the hippocampus following
tryptophan administration improves learning acquisition
and memory consolidation in rats. Pharmacol Rep 59,
53–57.
118. Coskun S, Ozer C, Gonul B, et al. (2006) The effect of
repeated tryptophan administration on body weight, food
intake, brain lipid peroxidation and serotonin immunoreac-
tivity in mice. Mol Cell Biochem 286, 133–138.
119. Hickman AB, Klein DC & Dyda F (1999) Melatonin biosyn-
thesis. Mol Cell 3, 23–32.
120. Bombardelli E & Morazzoni P (1995) Hypericum perfora-
tum. Fitoterapia 66, 43–68.
121. do Rego J-C, Benkiki N, Chosson E, et al. (2007) Anti-
depressant-like effect of hyperfoliatin, a polyisoprenylated
phloroglucinol derivative from Hypericum perfoliatum
(Clusiaceae) is associated with an inhibition of neuronal
monoamines uptake. Eur J Pharmacol 569, 197–203.
122. Sa´nchez-Mateo CC, Bonkanka CX & Rabanal RM (2009)
Hypericum grandifolium Choisy: a species native to Macar-
onesian region with antidepressant effect. J Ethnopharma-
col 121, 297–303.
123. Skalisz LL, Beijamini V & Andreatini R (2004) Effect of
Hypericum perforatum on marble-burying by mice. Phyt-
other Res 18, 399–402.
124. Viana A, do Rego J-C, von Poser G, et al. (2005) The anti-
depressant-like effect of Hypericum caprifoliatum Cham
& Schlecht (Guttiferae) on forced swimming test results
from an inhibition of neuronal monoamine uptake. Neuro-
pharmacology 49, 1042–1052.
125. Rodrigues AL, da Silva GL, Mateussi AS, et al. (2002) Invol-
vement of monoaminergic system in the antidepressant-like
effect of the hydroalcoholic extract of Siphocampylus verti-
cillatus. Life Sci 70, 1347–1358.
126. Jin Z-L, Gao N, Zhou D, et al. (2012) The extracts of Fructus
Akebiae, a preparation containing 90 % of the active ingre-
dient hederagenin: serotonin, norepinephrine and dopa-
mine reuptake inhibitor. Pharmacol Biochem Behav 100,
431–439.
127. Kno¨rle R (2012) Extracts of Sideritis scardica as triple
monoamine reuptake inhibitors. J Neural Transm 119,
1477–1482.
128. Ofir R, Tamir S, Khatib S, et al. (2003) Inhibition of seroto-
nin re-uptake by licorice constituents. J Mol Neurosci 20,
135–140.
129. Dhingra D, Parle M & Kulkarni SK (2004) Memory enhan-
cing activity of Glycyrrhiza glabra in mice. J Ethnopharma-
cology 91, 361–365.
130. Dhingra D & Sharma A (2006) Antidepressant-like activity
of Glycyrrhiza glabra L. in mouse models of immobility
tests. Prog Neuropsychopharmacol Biol Psychiatry 30,
449–454.
131. Mohajeri MH, Goralczyk R & Dimpfel W (2012) Modulation
of neurotransmission by a specified oregano extract alters
brain electrical potentials indicative of antidepressant-like
and neuroprotective activities. Neurosci Med 3, 37–46.
132. Bergstro¨m LS & Lyno¨e N (2008) Enhancing concentration,
mood and memory in healthy individuals: an empirical
study of attitudes among general practitioners and the gen-
eral population. Scand J Public Health 36, 532–537.
133. Owens M, Goodyer IM, Wilkinson P, et al. (2012) 5-HTTLPR
and early childhood adversities moderate cognitive and
emotional processing in adolescence. PLOS ONE 7, e48482.
134. Pratt LA, Brody DJ & Gu Q (2011) Antidepressant use in
persons aged 12 and over: United States, 2005–2008. In
NCHS Data Brief, no. 76. Hyattsville, MD: National Center
for Health Statistics.

















Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:48:22, subject to the Cambridge Core terms of use, available at
